{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:45:04Z","timestamp":1773294304951,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008145","name":"Florida Agency for Health Care Administration","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008145","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aims the following: (i) to describe the exposure to antipsychotic medications over a 4\u2010year period experienced by a cohort of children who initiated antipsychotic treatment before their sixth birthday; and (ii) to identify variables associated with the risk of antipsychotic exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Children were identified who initiated an index episode of antipsychotic treatment before their sixth birthday in Florida's fee for service Medicaid program. With the use of claims data, the medication utilization of these children was tracked during the year before and the 4\u2009years following the start of their index episodes (pre\u2010index and four post\u2010index periods). Generalized estimating equations were used to identify variables associated with the risk of additional days of antipsychotic exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five hundred twenty\u2010eight children were included in the cohort. The mean total number of days of exposure was 821.9 (\u00b1\u2009431.9), representing 56.3% of all days during the four post\u2010index periods. The mean days of exposure to combinations of antipsychotics and other classes of psychotherapeutic medications were 623.8\u2009\u00b1\u2009447.6\u2009days. Children with primary diagnoses of pervasive developmental disorders and affective disorders were at greater risk of additional days of exposure than children with attention deficit\/hyperactivity disorder. Exposure tended to be greater among children with indicators of clinical complexity including the presence of secondary diagnoses and the use of other classes of psychotherapeutic medications in addition to antipsychotics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Exposure to antipsychotic mediations was extensive. Although these children may have had complex and severe problems, additional research is urgently needed on the benefits and risks of long\u2010term antipsychotic exposure among very young children. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.2189","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T18:38:39Z","timestamp":1311705519000},"page":"152-160","source":"Crossref","is-referenced-by-count":16,"title":["Exposure to antipsychotic medications over a 4\u2010year period among children who initiated antipsychotic treatment before their sixth birthday"],"prefix":"10.1002","volume":"21","author":[{"given":"Robert J.","family":"Constantine","sequence":"first","affiliation":[{"name":"Florida Mental Health Institute University of South Florida  FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Jentz","sequence":"additional","affiliation":[{"name":"Florida Mental Health Institute University of South Florida  FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bengtson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of South Florida  FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"McPherson","sequence":"additional","affiliation":[{"name":"Florida Mental Health Institute University of South Florida  FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Andel","sequence":"additional","affiliation":[{"name":"Department of Aging Studies University of South Florida  FL USA"},{"name":"International Clinical Research Center St Ann's University Hospital  Brno Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Beth","family":"Jones","sequence":"additional","affiliation":[{"name":"Florida Agency for Health Care Administration  FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0006"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454602760386905"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G203"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2009.09.003"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011\u2010393X(02)80009\u20101"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583\u2010200110000\u201000015"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454604773840472"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.03.019"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787\u2010006\u20100580\u20101"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.3.402"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1361"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.575"},{"key":"e_1_2_10_14_1","unstructured":"U. S. Food and Drug Administration.Risperidone Aripiprazole Quetiapine and Olanzapine Drug Details.http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm[14 June 2010]."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.270"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.8.1059"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e3181570d9e"},{"key":"e_1_2_10_18_1","unstructured":"CorrellCU.Antipsychotic Use in Children. Physician's Weekly. Vol2011."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0039"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.59.5.554"},{"key":"e_1_2_10_21_1","article-title":"Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under six years old who received antipsychotic treatment in Florida's Medicaid program","author":"Constantine R","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_2_10_22_1","unstructured":"U.S. Food and Drug Administration: Center for Drug Evaluation and Research.National Drug Code Directory.http:\/\/www.fda.gov\/cder\/ndc\/database\/default.htm[14 July 2010]."},{"key":"e_1_2_10_23_1","first-page":"449","article-title":"Estimating medication persistency using administrative claims data","volume":"11","author":"Sikka R","year":"2005","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.08.042"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"e_1_2_10_26_1","volume-title":"The Use of Antipsychotic Medications in Children: A Comprehensive and Current View","author":"Constantine R","year":"2007"},{"key":"e_1_2_10_27_1","first-page":"585","article-title":"Use of atypical antipsychotics in children: balancing safety and effectiveness","volume":"81","author":"Kohlstadt I","year":"2010","journal-title":"Am Fam Physician"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2189","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.2189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:11:03Z","timestamp":1695510663000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.2189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1002\/pds.2189"],"URL":"https:\/\/doi.org\/10.1002\/pds.2189","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]}}}